MedTrace Logo

Anti-obesity Pharmacotherapy and Inflammation

NCT05756764 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2025-09-09

No results posted yet for this study

Summary

This study evaluates the relationship between weight loss, circulating inflammatory markers and lipids from 24 patients before and after 6 months of pharmacotherapy as a standard of care for anti-obesity treatment

Conditions

Interventions

DRUG

Semaglutide

Medication for weight loss

DRUG

Phentermine-Topiramate combination

Medication for weight loss

DRUG

Phentermine

Medication for weight loss

DRUG

Tirzepatide

Medication for weight loss

DRUG

Topiramate

Medication for weight loss

DRUG

Diethylpropion

Medication for weight loss

DRUG

Naltrexone/Bupropion

Medication for weight loss

DRUG

Liraglutide

Medication for weight loss

Sponsors & Collaborators

  • Tulane University

    collaborator OTHER

  • Pennington Biomedical Research Center

    collaborator OTHER

  • Ochsner Health System

    collaborator OTHER

  • Louisiana State University Health Sciences Center in New Orleans

    lead OTHER

Principal Investigators

  • Maria D Sanchez-Pino, Ph.D. · LSU-Health Sciences Center

Eligibility

Min Age
35 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2026-01-30
Completion
2026-02-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05756764 on ClinicalTrials.gov